Checkpoint Therapeutics Inc (NASDAQ:CKPT) has a beta value of 1.37 and has seen 1.12 million shares traded in the last trading session. The company, currently valued at $167.99M, closed the last trade at $3.44 per share which meant it lost -$0.22 on the day or -6.01% during that session. The CKPT stock price is -30.81% off its 52-week high price of $4.50 and 59.88% above the 52-week low of $1.38. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.12 million shares traded. The 3-month trading volume is 1.43 million shares.
The consensus among analysts is that Checkpoint Therapeutics Inc (CKPT) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight.
Checkpoint Therapeutics Inc (NASDAQ:CKPT) trade information
Sporting -6.01% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the CKPT stock price touched $3.44 or saw a rise of 8.75%. Year-to-date, Checkpoint Therapeutics Inc shares have moved 7.50%, while the 5-day performance has seen it change 2.69%. Over the past 30 days, the shares of Checkpoint Therapeutics Inc (NASDAQ:CKPT) have changed -17.51%. Short interest in the company has seen 5.56 million shares shorted with days to cover at 5.7.
Checkpoint Therapeutics Inc (CKPT) estimates and forecasts
Figures show that Checkpoint Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 58.53% over the past 6 months, with this year growth rate of 71.29%, compared to 16.90% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 26.32% over the past 5 years.
CKPT Dividends
Checkpoint Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Checkpoint Therapeutics Inc (NASDAQ:CKPT)’s Major holders
Insiders own 15.52% of the company shares, while shares held by institutions stand at 13.91% with a share float percentage of 16.47%. Investors are also buoyed by the number of investors in a company, with Checkpoint Therapeutics Inc having a total of 50.0 institutions that hold shares in the company.
